Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program-Reference-Cited by-同舟云学术

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program

Published:2022-01 Issue: Volume:57 Page:103350
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Salvetti Marco,Wray Sibyl,Nelles Gereon,Altincatal Arman,Kumar Achint,Koster Thijs,Naylor Maria L.

Funder

Biogen

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference27 articles.

1. Hypersensitivity reactions to biologicals: from bench to bedside;Akarsu;Curr. Treat. Options Allergy,2020

2. Multiple sclerosis in the elderly patient;Awad;Drugs Aging,2010

3. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study;Calabresi;Lancet Neurol.,2014

4. Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis;Filippi;Neurology,2001

5. Evolving expectations around early management of multiple sclerosis;Gold;Ther. Adv. Neurol. Disord.,2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for the Treatment of Multiple Sclerosis in Family Planning, Pregnancy and Lactation in Switzerland: Immunotherapy;Clinical and Translational Neuroscience;2024-08-01

2. Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

3. Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-β-1a Compared to Non-PEGylated IFN-β-1a;Journal of Interferon & Cytokine Research;2023-03-01

4. Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study;Med;2022-09